AR005339A1 - Anticuerpos monoclonales antiidiotipos (ab2) y sus usos - Google Patents

Anticuerpos monoclonales antiidiotipos (ab2) y sus usos

Info

Publication number
AR005339A1
AR005339A1 ARP970100004A ARP970100004A AR005339A1 AR 005339 A1 AR005339 A1 AR 005339A1 AR P970100004 A ARP970100004 A AR P970100004A AR P970100004 A ARP970100004 A AR P970100004A AR 005339 A1 AR005339 A1 AR 005339A1
Authority
AR
Argentina
Prior art keywords
monoclonal antibodies
antiidiotipes
idiotypes
mabs
immunotherapy
Prior art date
Application number
ARP970100004A
Other languages
English (en)
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of AR005339A1 publication Critical patent/AR005339A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con la rama de ina Inmunología y en particular con la selección y uso de anticuerpos monoclonales (AcM)antiidiotipos (AB2) de tipo IgG, que poseen la característica de presentar una alta conectividadidiotípic a y reconocimiento de los linfocitos B y T humanos,moléculas que de manera escencial participan en el desarrollo de la respuesta inmune por lo que pueden ser utilizados en la inmunoterapia de las enfermedadesautoinmunes, infecciosas ycáncer.
ARP970100004A 1996-01-05 1997-01-02 Anticuerpos monoclonales antiidiotipos (ab2) y sus usos AR005339A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9600235.7A GB9600235D0 (en) 1996-01-05 1996-01-05 Therapeutic agents

Publications (1)

Publication Number Publication Date
AR005339A1 true AR005339A1 (es) 1999-04-28

Family

ID=10786682

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP970100004A AR005339A1 (es) 1996-01-05 1997-01-02 Anticuerpos monoclonales antiidiotipos (ab2) y sus usos
ARP970100003A AR005338A1 (es) 1996-01-05 1997-01-02 Derivados acetidinalquilicos de heterociclos con nitrogeno n-sustituido o sales farmaceuticamente aceptables de los mismos, un procedimiento paraprepararlos, composiciones farmaceuticas que los comprenden, uso de dichos derivados, sales y composiciones, y compuestos utilizables como intermedios

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP970100003A AR005338A1 (es) 1996-01-05 1997-01-02 Derivados acetidinalquilicos de heterociclos con nitrogeno n-sustituido o sales farmaceuticamente aceptables de los mismos, un procedimiento paraprepararlos, composiciones farmaceuticas que los comprenden, uso de dichos derivados, sales y composiciones, y compuestos utilizables como intermedios

Country Status (38)

Country Link
US (1) US6242438B1 (es)
EP (1) EP0871623B1 (es)
JP (2) JP3123611B2 (es)
KR (1) KR100275402B1 (es)
AP (1) AP709A (es)
AR (2) AR005339A1 (es)
AT (1) ATE232526T1 (es)
AU (1) AU708282B2 (es)
BG (1) BG102589A (es)
BR (1) BR9612412A (es)
CA (1) CA2237189C (es)
CO (1) CO4750815A1 (es)
CZ (1) CZ209398A3 (es)
DE (1) DE69626220T2 (es)
DK (1) DK0871623T3 (es)
DZ (1) DZ2155A1 (es)
ES (1) ES2190486T3 (es)
GB (1) GB9600235D0 (es)
HR (1) HRP970006A2 (es)
HU (1) HUP9903590A3 (es)
IL (2) IL145324A0 (es)
IS (1) IS1876B (es)
MA (1) MA26417A1 (es)
NO (1) NO311838B1 (es)
NZ (1) NZ324712A (es)
OA (1) OA10863A (es)
PE (1) PE29798A1 (es)
PL (1) PL185723B1 (es)
RU (1) RU2158264C2 (es)
SI (1) SI0871623T1 (es)
SK (1) SK89598A3 (es)
TN (1) TNSN96174A1 (es)
TR (1) TR199801268T2 (es)
TW (1) TW472054B (es)
UY (1) UY24429A1 (es)
WO (1) WO1997025322A1 (es)
YU (1) YU71496A (es)
ZA (1) ZA9747B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714129D0 (en) * 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
AU1089599A (en) * 1997-10-15 1999-05-03 Coelacanth Chemical Corporation Synthesis of azetidine derivatives
CN1121398C (zh) 1997-12-04 2003-09-17 三共株式会社 脂环式酰化杂环衍生物
GB9821898D0 (en) * 1998-10-08 1998-12-02 Pfizer Ltd Heterocycles
CA2412355A1 (en) * 2000-06-12 2001-12-20 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
US6642226B2 (en) * 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
GB0130261D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Lactams as tachykinin antagonists
US7674783B2 (en) * 2002-11-22 2010-03-09 Dimera Inc. Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
ES2282731T3 (es) * 2002-12-23 2007-10-16 Janssen Pharmaceutica N.V. Derivados de 1-piperidin-4-il-4-azetidin-3-il-piperazina sustituida y su uso como antagonistas de neuroquininas.
TW200508221A (en) 2003-06-13 2005-03-01 Astrazeneca Ab New azetidine compounds
CA2589565A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
CA2570637A1 (en) 2004-06-24 2006-02-02 Wenqing Yao N-substituted piperidines and their use as pharmaceuticals
BRPI0608847A2 (pt) 2005-03-08 2010-02-02 Janssen Pharmaceutica Nv derivados de diaza-espiro-[4,4]-nonano substituìdos e seu uso como antagonistas de neurocinina
AR057828A1 (es) 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
US8106208B2 (en) 2006-05-18 2012-01-31 Albireo Ab Benzamide compounds that act as NK receptor antagonists
JP2010516734A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物
AR074755A1 (es) * 2008-12-16 2011-02-09 Astrazeneca Ab Derivados cuaternarios de piperidina y sus usos
JP2012524807A (ja) * 2009-04-22 2012-10-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
WO1994026735A1 (en) * 1993-05-06 1994-11-24 Merrell Dow Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists
FR2719311B1 (fr) * 1994-03-18 1998-06-26 Sanofi Sa Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic.
TW432061B (en) 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
GB9601202D0 (en) * 1996-01-22 1996-03-20 Pfizer Ltd Piperidones
GB9812037D0 (en) * 1998-06-04 1998-07-29 Pfizer Ltd Piperidones
GB9821898D0 (en) * 1998-10-08 1998-12-02 Pfizer Ltd Heterocycles

Also Published As

Publication number Publication date
YU71496A (en) 1999-11-22
CO4750815A1 (es) 1999-03-31
IL124309A (en) 2002-11-10
HUP9903590A2 (hu) 2000-05-28
IS1876B (is) 2003-05-28
RU2158264C2 (ru) 2000-10-27
IL124309A0 (en) 1998-12-06
DE69626220T2 (de) 2003-08-28
PL185723B1 (pl) 2003-07-31
DZ2155A1 (fr) 2002-10-26
EP0871623B1 (en) 2003-02-12
GB9600235D0 (en) 1996-03-06
SK89598A3 (en) 2000-02-14
SI0871623T1 (en) 2003-08-31
MA26417A1 (fr) 2004-12-20
HUP9903590A3 (en) 2002-01-28
NZ324712A (en) 1999-05-28
NO311838B1 (no) 2002-02-04
UY24429A1 (es) 2001-08-27
IL145324A0 (en) 2002-06-30
KR100275402B1 (ko) 2000-12-15
ES2190486T3 (es) 2003-08-01
ZA9747B (en) 1998-09-30
HRP970006A2 (en) 1998-06-30
BR9612412A (pt) 1999-07-13
CA2237189A1 (en) 1997-07-17
AP709A (en) 1998-12-22
NO982651L (no) 1998-06-09
CA2237189C (en) 2002-09-03
EP0871623A1 (en) 1998-10-21
JPH11501667A (ja) 1999-02-09
AP9600901A0 (en) 1997-01-31
OA10863A (en) 2001-09-27
TW472054B (en) 2002-01-11
AU708282B2 (en) 1999-07-29
ATE232526T1 (de) 2003-02-15
NO982651D0 (no) 1998-06-09
US6242438B1 (en) 2001-06-05
DE69626220D1 (de) 2003-03-20
PE29798A1 (es) 1998-06-11
JP2000344741A (ja) 2000-12-12
WO1997025322A1 (en) 1997-07-17
PL327665A1 (en) 1998-12-21
JP3254205B2 (ja) 2002-02-04
DK0871623T3 (da) 2003-03-31
BG102589A (en) 1999-09-30
TR199801268T2 (xx) 1998-10-21
CZ209398A3 (cs) 1999-04-14
AU1195097A (en) 1997-08-01
IS4760A (is) 1998-05-28
JP3123611B2 (ja) 2001-01-15
TNSN96174A1 (fr) 2005-03-15
KR19990077027A (ko) 1999-10-25
AR005338A1 (es) 1999-04-28

Similar Documents

Publication Publication Date Title
AR005339A1 (es) Anticuerpos monoclonales antiidiotipos (ab2) y sus usos
ATE113845T1 (de) Monoklonale antikörper gegen glycolipid-antigene und ihre verwendung.
NO933179D0 (no) Anti-idiotype antistoffer overfor human melanoma-assosiert proteoglykanantigen
DK0796280T3 (da) Murint monoklonalt anti-idiotypisk antistof 3H1
ES2165864T3 (es) Anticuerpos humanizados.
DK0432249T3 (da) Monoklonale antistoffer over for beta-kæden i leukocytadhæsionsreceptoren, fremgangsmåder til fremstilling af disse antistoffer og anvendelse heraf
DE69504959D1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
CU22585A1 (es) Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
ATE119203T1 (de) Monoklonale antikörper von mäusen gegen das gp41 protein von menschlichem immunmangelsyndrom- virus.
DK0825256T3 (da) Hybridcelle og dens anvendelse til fremstilling af et lægemiddel til inducering af en tumorimmunitet
DE69111429T2 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
DK616989A (da) Humane monoklonale antistoffer, der specifikt genkender rabiesvirusceller, celler, der prducerer denne virus, formuleringer, der indeholder virusen, samt fremstilling af disse antistoffer
NO900216L (no) Anti-idiotype antistoff mot anti-human melanom-assosiert antigen med hoey molekylvekt.
CU22500A1 (es) Anticuerpos monoclonales anti-gangliosidos, anticuerpos monoclonales antiidiotipos, hibridomas productores y procedimiento de obtención de los mismos
DK373389D0 (da) Fremgangsmaade til selektion af anti-idiotype antistoffer og anvendelse af disse til diagnostiske og terapeutiske formaal